Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-11-06

FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application to allow Mylan Pharmaceuticals to market a generic spironolactone and hydrochlorothiazide combination for treating hyper…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Spironolactone and Hydrochlorothiazide (Spironolactone; Hydrochlorothiazide)

Snippet

SUPPL AP for SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE)